Buerger’s Disease (Thromboangiitis Obliterans): Causes, Symptoms, and Treatment

What is Buerger’s disease (thromboangiitis obliterans)?

Photo credit: Shutterstock.com

Buerger’s disease (thromboangiitis obliterans) is a non-atherosclerotic segmental vasculitis that predominantly affects small and medium-sized arteries and veins, particularly in the distal extremities (hands and feet). The pathology was first described by American physician Leo Buerger in 1908 and has since been recognized as a distinct entity within the spectrum of inflammatory vascular disorders.

Unlike classic obstructive arteriopathies, particularly those caused by atherosclerosis, thromboangiitis obliterans occurs in young individuals, often between 20 and 40 years of age, with a clear and direct association with active tobacco consumption. The incidence is significantly higher in males, but cases among female smokers are increasing, reflecting behavioral changes in recent decades.

Histopathologically, the disease is characterized by transmural inflammation of the vessels, accompanied by luminal thrombosis rich in mononuclear cells and granulocytes, with relative preservation of the vascular wall architecture and no evident signs of atheroma. The formation of collateral networks with a spiral morphology, often described as “corkscrew,” is a distinctive imaging feature, useful for differential diagnosis from other peripheral arteriopathies.

Pathogenesis of the disease – autoimmune and inflammatory mechanism

The pathogenesis of the disease is not fully elucidated, but current data support an autoimmune mechanism triggered by toxic compounds derived from tobacco, involving genetic predisposition and endothelial dysfunction. Chronic exposure to these toxins induces an aberrant immune response, with activation of inflammatory cascades and progressive destruction of the microvasculature. Thus, this combination of proinflammatory and procoagulant factors contributes to disease progression and the occurrence of distal ischemia, sometimes leading to necrosis and gangrene.

Disease management is primarily based on the complete cessation of tobacco consumption, the only proven intervention that can slow or stop progression. In advanced cases, vasodilatory therapies, revascularization techniques (where possible), and management of ischemic pain may be used. Prognosis essentially depends on the timing of diagnosis and strict adherence to smoking cessation.

In the context of preventing peripheral vascular diseases and maintaining optimal vascular function, adjuvant approaches can play a beneficial role. Cardio Help, a natural supplement formulated with extracts from 9 plants and superfruits with vasoprotective properties, contributes to supporting vascular wall elasticity and improving peripheral circulation. Through its antioxidant and anti-inflammatory action, this product can be an effective complement to strategies for supporting vascular health, especially for patients at high risk of microcirculatory diseases.

[cta_produs style=”style_1″ product=”349242″ image=”https://aronia-charlottenburg.com/wp-content/uploads/2025/04/Ce-este-boala-Buerger-trombangeita-obliteranta_-Aronia-HERO-product.jpg”]

Epidemiology and risk factors of thromboangiitis obliterans

Thromboangiitis obliterans has uneven geographical prevalence, with heterogeneous distribution depending on the region. High-incidence regions include the Middle East, South and Southeast Asia (especially India), and East Asia (including Japan and Korea), where the condition can account for 40% to 60% of all peripheral arterial disease cases. In contrast, in Western Europe and North America, the prevalence is significantly lower, ranging from 0.5% to 5%. This regional variability suggests both genetic and behavioral influences in the pathogenesis of the disease.

In Romania, the exact prevalence is unknown due to the lack of robust epidemiological data, but there are indications that the disease is considerably underdiagnosed, especially in the absence of specific clinical criteria and etiological suspicion among clinicians.

Thromboangiitis obliterans – demographic profile

The demographic profile of patients with thromboangiitis obliterans is clearly defined. The disease predominantly affects young adults, typically with onset around 30–40 years of age. Approximately 80% of cases are diagnosed before the age of 45. The male sex is significantly more frequently affected, with a male:female ratio varying between 3:1 and 10:1, depending on the population studied. A higher prevalence has also been observed in certain ethnic groups, with a notably higher incidence among Ashkenazi Jewish, Japanese, and Indian populations, supporting the possibility of a genetic substrate in the etiopathogenesis of the disease.

Active smoking remains, undoubtedly, the major and indispensable risk factor for the development of Buerger’s disease. Over 95% of diagnosed patients are active smokers or have a recent history of tobacco exposure. Studies have demonstrated a clear dose-effect relationship between tobacco consumption (regardless of the form used: cigarettes, cigars, pipes, chewing tobacco) and the clinical severity of the disease. The peculiarity of thromboangiitis obliterans, compared to other peripheral arteriopathies, lies in the persistence of disease activity even at low doses of nicotine exposure, making complete smoking cessation imperative to prevent the progression of tissue ischemia.

Symptoms and clinical manifestations of Buerger’s disease

The clinical manifestations of thromboangiitis obliterans are, in the early stages, non-specific and can be easily confused with other forms of peripheral vascular disease. Symptoms typically begin insidiously, with progressive onset, reflecting predominant involvement of small and medium-sized distal arteries.

Intermittent claudication is the most common initial symptom and is often localized distally, particularly on the plantar surface or toes, unlike atherosclerotic arteriopathy, where the localization is more proximal (calves, thighs). Exercise-induced pain typically appears after walking a certain distance and resolves with rest, but as the ischemic process worsens, the claudication distance progressively decreases, indicating worsening circulatory obstruction.

Photo credit: Shutterstock.com

Raynaud phenomenon – severe vasomotor

An important additional sign is Raynaud phenomenon, reported in 40–50% of patients, indicating severe digital arteriolar vasomotor dysfunction. It manifests as episodes of reversible vasospasm, triggered by exposure to cold or emotional stress, with triphasic skin color changes (pallor – cyanosis – reactive erythema), often accompanied by paresthesias, tingling, or numbness, as well as hypersensitivity to low temperatures.

Disease progression leads to a transition from exertional ischemia to rest ischemia, characterized by persistent, deep burning pain localized in the fingers, often nocturnal, intensified in the supine position, and partially relieved by lowering the affected limb (pendulum maneuver).

In advanced forms, trophic skin lesions appear, particularly ischemic ulcers, located in areas of minor pressure or trauma – most commonly on the fingertips. The lesions are deeply painful, poorly vascularized, with reduced tendency for spontaneous healing and an increased risk of bacterial superinfection. In the absence of adequate therapeutic intervention and smoking cessation, the progression can culminate in dry or wet gangrene, often requiring segmental amputation.

Diagnosis of thromboangiitis obliterans

Establishing the diagnosis of thromboangiitis obliterans involves careful integration of clinical and paraclinical data, given its exclusionary nature and partial overlap with other vascular entities.

In clinical practice, the criteria proposed by Shionoya are frequently used to guide diagnosis, providing a standardized framework with high sensitivity and specificity. These include: history of tobacco use, onset of vascular symptoms before the age of 50, segmental involvement of infra-popliteal arteries, vascular involvement of the upper limbs or presence of migratory thrombophlebitis, and absence of major atherosclerotic risk factors other than smoking. Co-occurrence of the five criteria highly supports the existence of Buerger’s disease.

Detailed clinical evaluation remains essential for initial diagnostic suspicion. Inspection of the extremities may reveal trophic skin changes, distal ischemic lesions, or, in advanced cases, limited areas of gangrene. Palpation of peripheral pulses, often absent distally, is useful in quantifying the degree of hemodynamic involvement. Measuring local temperature and capillary refill time completes the objective circulatory assessment. In the upper limbs, the Allen test can provide relevant information about the patency of the radial and ulnar arterial systems, indicated in cases of digital ischemia or suspected forearm artery involvement.

Paraclinical investigations – positive diagnosis

Positive diagnosis and exclusion of other etiologies are based on a set of targeted paraclinical investigations. The usual biological profile (complete blood count, non-specific inflammatory markers such as ESR and C-reactive protein) generally remains within normal limits or shows minimal variations, supporting the non-systemic nature of the inflammatory process. Metabolic measurements (blood glucose, glycated hemoglobin, lipid profile) primarily serve to exclude atherosclerotic pathology and diabetes mellitus – conditions frequently associated with peripheral ischemia in other etiological contexts.

However, vascular imaging is the cornerstone of diagnosis confirmation. Conventional angiography remains the reference investigation, revealing segmental occlusive lesions of small and medium-sized arteries, with preservation of patency in major proximal vessels. The typical appearance consists of collateral networks with a spiral course – classically described as “corkscrew” – which partially compensate for distal ischemia. These angiographic characteristics differentiate it from the continuous, progressive, and diffuse lesions found in atherosclerotic arteriopathy.

A comprehensive, correctly staged evaluation, guided by clinical criteria and paraclinical data, is essential for early diagnosis and prompt implementation of therapeutic measures, including definitive smoking cessation, the only intervention with a proven impact on disease progression.

Therapeutic approaches in Buerger’s disease

The therapeutic management of thromboangiitis obliterans involves a complex, multidisciplinary approach aimed at restoring tissue perfusion, controlling ischemic pain, and preventing the progression of distal vascular lesions. The main objective remains to maintain the viability of the affected limb and prevent limb-threatening complications, including amputation.

The first and most important therapeutic step is complete and definitive cessation of tobacco consumption, regardless of its form (cigarettes, cigars, pipes, chewing tobacco). Clinical evidence supports a direct correlation between stopping tobacco use and reducing the risk of ischemic complications. Compared to patients who continue to smoke, where the long-term amputation rate reaches 40–50%, those who quit completely have an incidence below 5%. Furthermore, it should be noted that even passive exposure to tobacco smoke or occasional relapses can reactivate the inflammatory process and maintain disease activity.

Pharmacological therapy – role and therapeutic options

In parallel with lifestyle modification measures, pharmacological therapy plays an adjuvant role in alleviating symptoms and supporting peripheral perfusion. Synthetic prostacyclins, such as iloprost or alprostadil, administered intravenously, have proven effective in reducing rest pain and accelerating the healing of ischemic ulcers. Their vasodilatory and antiplatelet effects contribute to improving microcirculation, especially in acute phases of the disease. Additionally, calcium channel blockers (e.g., nifedipine, diltiazem) and phosphodiesterase III inhibitors (e.g., cilostazol) can be used to improve distal arterial flow by reducing peripheral vascular resistance and increasing blood flow. Platelet aggregation inhibitors (acetylsalicylic acid, clopidogrel) are also indicated prophylactically to reduce the risk of intraluminal thrombosis.

To optimize therapeutic response, the integration of non-pharmacological interventions is recommended, with additive value in reducing symptoms and preventing ischemic complications. Intermittent pneumatic compression, applied sequentially, stimulates venous and lymphatic circulation, indirectly contributing to improved tissue oxygenation. At the same time, supervised exercise programs promote the development of collateral networks and can increase walking distance without pain in patients with intermittent claudication.

In cases refractory to conventional treatments, especially in patients with severe rest pain or extensive ischemic ulcers, advanced techniques may be considered. Epidural spinal cord electrical stimulation can modulate pain perception through complex neurophysiological mechanisms, and hyperbaric oxygen therapy supports the healing of ischemic lesions by increasing tissue partial pressure of oxygen.

Emerging therapies and recent research in thromboangiitis obliterans

Recent advances in understanding the pathophysiological mechanisms involved in thromboangiitis obliterans have led to the development of innovative therapeutic directions, especially for patients with advanced forms refractory to conventional treatments. Regenerative interventions and targeted molecular therapies offer solid premises for personalized approaches with the potential to modify the natural course of the disease.

Stem cell therapy with hematopoietic or mesenchymal stem cells has shown encouraging results in reducing ischemic symptomatology and promoting therapeutic angiogenesis. Intramuscular implantation of autologous mononuclear cells derived from bone marrow has been associated with improved rest pain, reduced size of ischemic ulcers, and decreased incidence of amputations in the context of critical limb ischemia. The proposed mechanism involves the secretion of angiogenic factors (VEGF, HGF, bFGF) and direct contribution to neovascularization through endothelial differentiation and recruitment of vascular progenitor cells, with improved regional tissue perfusion.

On the other hand, gene therapy has emerged as another promising approach for inducing angiogenesis in areas inaccessible to surgical revascularization. Local administration of genes encoding vascular growth factors (such as VEGF or FGF), via viral vectors (adenoviruses, lentiviruses) or non-viral plasmids, aims to stimulate vasculogenesis and increase blood flow in ischemic territories. Preclinical studies and early-phase clinical trials have demonstrated improved tissue oxygenation, reduced pain, and, in some cases, healing of trophic lesions, suggesting significant functional benefit.

Thromboangiitis obliterans – molecular research directions

Furthermore, current molecular research directions in thromboangiitis obliterans aim to identify specific biomarkers with predictive and prognostic value. The development of tests based on the expression of inflammatory genes and endothelial mediators can enable early diagnosis and dynamic monitoring of treatment response. Simultaneously, unraveling gene-environment interactions, particularly between genetic polymorphisms and chronic nicotine exposure, offers prospects for implementing personalized prevention strategies in at-risk population groups.

An emerging direction is the exploration of the oral microbiome, in the context of a possible causal relationship between periodontal infections and systemic immune activation observed in thromboangiitis obliterans. Oral dysbiosis could contribute, through common inflammatory and molecular mechanisms, to the initiation or exacerbation of segmental vascular processes, a hypothesis that could support prophylactic interventions at the level of oral health as an integral part of the global therapeutic plan.

Overall, the integration of new biological, cellular, and genetic approaches can fundamentally transform the therapeutic paradigm of thromboangiitis obliterans, focusing on early, regenerative, and personalized interventions tailored to the patient’s molecular and clinical profile.

Complications and prognosis of Buerger’s disease

Thromboangiitis obliterans has a severe evolutionary potential. Severity is higher in the absence of definitive smoking cessation. Disease progression is marked by chronic tissue ischemia. Chronic tissue ischemia can lead to irreversible damage to peripheral tissues. One of the most frequent complications is chronic ischemic ulcers. These are predominantly located on the fingertips. These are predominantly located on the toes. The lesions are characterized by intense pain. The lesions are characterized by healing difficulties. The lesions have increased resistance to conventional therapies. The lesions are often accompanied by a major risk of bacterial superinfection.

In advanced stages, untreated ischemia can progress to dry gangrene. In advanced stages, untreated ischemia can progress to wet gangrene. Onset is frequent distally (digital). Extension is potentially proximal. The need for amputations becomes a clinical reality in the absence of control of the main triggering factor. The main triggering factor is exposure to tobacco. The risk of amputation is significantly amplified in patients who continue to smoke.

The prognosis of patients with thromboangiitis obliterans fundamentally depends on compliance with definitive smoking cessation. Smoking cessation is the most relevant predictor of long-term outcome. According to data from the literature, patients who completely stop tobacco use have an amputation rate below 5%. The amputation rate is compared to 40–50% in those who continue to smoke in the first 7–8 years of evolution.

Prognostic factors

In addition to smoking status, the clinical stage at diagnosis, as well as the response to instituted therapies, significantly influence disease progression. Early therapeutic intervention, before the onset of critical ischemia or trophic lesions, is associated with a favorable functional prognosis.

For example, long-term cohort studies have shown that, in patients who definitively quit smoking, the clinical outcome is often stabilized. Symptomatic relief is observed. A decrease in the frequency of ischemic episodes is observed. It is estimated that approximately 85–90% of these patients avoid major amputations over a period of 10–20 years. However, residual manifestations may persist. Examples of residual manifestations include mild intermittent claudication. Another example is Raynaud phenomenon. These may persist even in the context of causal factor cessation.

In terms of general mortality, thromboangiitis obliterans is not associated with a significantly increased risk compared to the general population. This is true in the absence of rare systemic complications. Thus, long-term survival is influenced more by functional disability caused by ischemia than by direct lethal risks. Implementing an early diagnosis strategy is a key element for preserving quality of life. Implementing individualized management is a key element for preserving quality of life. The focus must be on preventing disease progression. Implementing an early diagnosis strategy is a key element for reducing major complications. Implementing individualized management is a key element for reducing major complications. The focus must be on preventing disease progression.

Prevention strategies in Buerger’s disease management

Photo credit: Shutterstock.com

Prevention is an essential pillar in the modern approach to thromboangiitis obliterans. It has a dual role: limiting disease incidence in individuals at increased risk (primary prevention). It has a dual role: reducing complications in already diagnosed patients (secondary prevention). Essentially, both directions involve structured interventions. These interventions involve the medical system. These interventions also involve public health policies.

In the context of primary prevention, the focus is on educating the general population. The focus is particularly on educating young people. Education targets the risks of smoking. Smoking is the main etiological cause associated with thromboangiitis obliterans. Information campaigns significantly contribute to raising awareness. Counseling significantly contributes to raising awareness. These take place in schools. These take place in universities. These take place through digital platforms. Additionally, the implementation of public health measures has proven effective in reducing smoking prevalence. Examples of measures include additional taxation of tobacco products. Examples of measures include limiting exposure in public spaces. Examples of measures include graphic warnings on product packaging. Reducing smoking prevalence implicitly leads to disease reduction.

Early detection of peripheral ischemia

For exposed individuals, clinical screening becomes a valuable tool for early detection of signs of peripheral ischemia. Exposure is particularly relevant for active smokers under the age of 45. Careful physical examination of peripheral pulses may identify functional deviations suggestive of Buerger’s disease. Determination of the ankle-brachial index may identify functional deviations suggestive of Buerger’s disease. Performing the Allen test on the upper limbs may identify functional deviations suggestive of Buerger’s disease. Identification occurs before irreversible lesions develop. The occurrence of symptoms should be promptly investigated. An example of a symptom is atypical claudication (distally localized). An example of a symptom is recurrent Raynaud phenomenon. An example of a symptom is discomfort in the extremities. Investigation is particularly important in people without traditional atherosclerotic risk factors.

Secondary prevention

For patients with a confirmed diagnosis, secondary prevention focuses on preventing ischemic complications. Secondary prevention focuses on preserving the function of the affected limb. Definitive smoking cessation is the absolute condition for stabilizing disease progression. Cessation is supported through integrated smoking cessation programs. These include personalized psychological counseling. They include nicotine replacement therapy. They include pharmacological treatments (e.g., bupropion, varenicline). They include support groups.

Concurrently, patients must be educated about self-monitoring of their peripheral status. This is done through daily inspection of the extremities. Through rigorous skin hygiene. By wearing appropriate footwear. By avoiding exposure to cold. Furthermore, inclusion in a supervised exercise program can stimulate the development of collateral circulation. An example of exercises is treadmill walking with graded breaks. It can contribute to improving tissue perfusion.

Vasoprotective benefits

At the same time, to support vascular function, the use of natural supplements with vasoprotective action can be recommended as an adjuvant. An example is Cardio Help. This is a phytotherapeutic complex. It contains extracts from 9 plants and superfruits. It has antioxidant properties. It has anti-inflammatory properties. It has vasodilatory properties. Regular administration can support vascular elasticity. It can support peripheral circulation. It can bring benefits as part of an integrated prevention strategy. It can bring benefits as part of an integrated strategy for maintaining cardiovascular health. The benefits are particularly for patients with microvascular involvement. The benefits are particularly for patients at risk of ischemic progression.

Summarizing the information presented above, adopting preventive measures can significantly alter the natural trajectory of the disease. Measures are taken in a personalized framework. Measures are taken in a coordinated multidisciplinary framework. The effect is a reduction in the risk of severe complications. The effect is an improvement in long-term quality of life.

In conclusion, thromboangiitis obliterans represents a severe clinical entity. It has a destructive evolutionary potential in the absence of adequate therapeutic management. Definitive smoking cessation is the essential measure for controlling disease progression. It directly impacts the risk of critical ischemia. It directly impacts the risk of amputation. Furthermore, early intervention offers a real chance for clinical stabilization. The intervention is supported by rigorous vascular monitoring. The intervention integrates pharmacological therapies. The intervention integrates regenerative therapies.

References:

1. Olin, J. W. (2000). Thromboangiitis obliterans (Buerger’s disease). New England Journal of Medicine, 343(12), 864-869. https://www.nejm.org/doi/full/10.1056/NEJM200009213431207;
2. Klein-Weigel, P. F., Richter, J. G. (2014). Thromboangiitis obliterans (Buerger’s disease). Vasa, 43(5), 337-346. https://econtent.hogrefe.com/doi/10.1024/0301-1526/a000371;
3. Fazeli, B., Rezaee, S. A. (2011). A review on thromboangiitis obliterans pathophysiology: thrombosis and angiitis, which is to blame? Vascular, 19(3), 141-153. https://journals.sagepub.com/doi/10.1258/vasc.2010.ra0045;
4. Cacione, D. G., Macedo, C. R., Baptista-Silva, J. C. C. (2016). Pharmacological treatment for Buerger’s disease. Cochrane Database of Systematic Reviews, (3). https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011033.pub3/full;
5. Vijayakumar, A., Tiwari, R., Kumar Prabhuswamy, V. (2013). Thromboangiitis obliterans (Buerger’s Disease)—Current Practices. International Journal of Inflammation, 2013. https://www.hindawi.com/journals/iji/2013/156905/.

Photo credit: Shutterstock.com